Wolfgang A Weber, 5812 Stafford Pl, Larchmont, NY 10538

2020036, Nov 19, 2020

Dec 12, 2019

16/712919

- New York NY, US
Thomas REINER - New York NY, US
Wolfgang WEBER - New York NY, US
Snehal G. PATEL - New York NY, US

Memorial Sloan Kettering Cancer Center - New York NY

A61K 49/00
A61B 5/00
A61B 5/055
A61K 9/00

The present disclosure describes methods of use of a composition comprising PARPi-fl to be administered to the oral cavity (e.g., via topical application to surfaces of the oral cavity) followed by imaging of the oral cavity for detection of squamous cell carcinoma of the oral cavity (e.g., in vivo, e.g., in a dental office setting or intraoperatively). The results disclosed herein show that topically applied PARPi-fl and subsequent intraoperative imaging of oral cavities can improve surgical removal of squamous cell carcinoma cells compared to healthy cells.

2019028, Sep 19, 2019

Nov 29, 2017

16/463865

- New York NY, US
- Ithaca NY, US
- Columbia MO, US
Wolfgang Weber - Larchmont NY, US
Karim Touijer - New York NY, US
Howard Scher - Tenafly NJ, US
Kai Ma - Ithaca NY, US
Ulrich Wiesner - Ithaca NY, US

A61K 49/00
A61K 51/08
A61K 51/12
C07K 7/02

Described herein are novel conjugates containing an inhibitor (e.g., a PSMA inhibitor, e.g., a gastrin-releasing peptide receptor inhibitor) and metal chelator that are covalently attached to a macromolecule (e.g., a nanoparticle, a polymer, a protein). Such conjugates exhibit distinct properties over the free, unbound inhibitor/chelator construct.

2019004, Feb 14, 2019

Apr 8, 2016

15/565369

- New York NY, US
Thomas REINER - New York NY, US
Wolfgang WEBER - New York NY, US
Snehal G. PATEL - New York NY, US

Memorial Sloan Kettering Cancer Center - New York NY

A61K 49/00
A61B 5/00
A61B 5/055
A61K 9/00

The present disclosure describes methods of use of a composition comprising PARPi-fl to be administered to the oral cavity (e.g., via topical application to surfaces of the oral cavity) followed by imaging of the oral cavity for detection of squamous cell carcinoma of the oral cavity (e.g., in vivo, e.g., in a dental office setting or intraoperatively). The results disclosed herein show that topically applied PARPi-fl and subsequent intraoperative imaging of oral cavities can improve surgical removal of squamous cell carcinoma cells compared to healthy cells.

2017026, Sep 21, 2017

Aug 27, 2015

15/506001

- New York NY, US
Jason S. Lewis - New York NY, US
Wolfgang Weber - Larchmont NY, US
Beatriz Salinas Rodriguez - Madrid, ES
Brandon Carney - Brooklyn NY, US
Giuseppe Carlucci - New York NY, US

A61K 51/04
C07F 5/02
C07D 237/32

Disclosed are chemical entities of formula (I) wherein R, Rand n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1 is overexpressed.

2016008, Mar 24, 2016

Jul 25, 2014

14/889079

- New York NY, US
Christian Brand - New York NY, US
Jason Lewis - New York NY, US
Wolfgang Weber - Larchmont NY, US

Sloan-Kettering Institute for Cancer Research - New York NY

A61K 51/08

A chemical compound has the general formula: Ex4-linker-Sar(Cu)-Fl in which Ex4 is an extendin-4 analog; linker is a polyethylene glycol (PEG) chain, for example formed with four ethylene glycol residues; Fl is a photoluminescent moiety, and Sar(Cu) is an atom of copper-64 chelated in a sarcophagine moiety is useful as a multimodality imaging agent for detection and localization of insulinoma cells and β-cell masses.